China's NHSA Issues Guidelines for Neurological Medical Services Pricing
Medical DevicePolicy / Regulatory

China’s NHSA Issues Guidelines for Neurological Medical Services Pricing

Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
Company

Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth

Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services
CompanyDigital

Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services

Jiuzhitang's Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval
CompanyDrug

Jiuzhitang’s Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval

Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery
Company

Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery

Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases
CompanyDeals

Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases

Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production
CompanyDeals

Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production

Novartis' Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
CompanyDrug

Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
Company

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results

Ono Pharmaceutical Licenses Ionis' Sapablursen for Global Development in Polycythemia Vera
CompanyDeals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Boehringer Ingelheim One Medicine Platform Veeva Systems
CompanyDeals

Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
CompanyDrug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients